TrialBMC pediatrics2010
A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
Pilar Fernández et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
26 papers cite it
this paperpooled itcites it